To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

December 20, 2022

Conditions

Von Willebrand's Disease (VWD)

Interventions

DRUG

efanesoctocog alfa (BIVV001)

Pharmaceutical form:solution for injection Route of administration: intravenous injection

Trial Locations (4)

Hemophilia Center of Western Pennsylvania_Investigational Site Number :8400001, Pittsburgh

Investigational Site Number :2500002, Nantes

University of Iowa_Investigational Site Number :8400002, Iowa City

Investigational Site Number :2500001, Lille

All Listed Sponsors

lead

Bioverativ, a Sanofi company

INDUSTRY